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Abstract
Purpose: The purpose of this meta-analysis was to determine the strength of the association between gynecologic
surgeries, tubal ligation and hysterectomy, and ovarian cancer.
Methods: We searched the PubMed, Web of Science, and Embase databases for all English-language articles dated
between 1969 through March 2011 using the keywords “ovarian cancer” and “tubal ligation” or “tubal sterilization”
or “hysterectomy.” We identified 30 studies on tubal ligation and 24 studies on hysterectomy that provided relative
risks for ovarian cancer and a p-value or 95% confidence interval (CI) to include in the meta-analysis. Summary RRs
and 95% CIs were calculated using a random-effects model.
Results: The summary RR for women with vs. without tubal ligation was 0.70 (95%CI: 0.64, 0.75). Similarly, the
summary RR for women with vs. without hysterectomy was 0.74 (95%CI: 0.65, 0.84). Simple hysterectomy and
hysterectomy with unilateral oophorectomy were associated with a similar decrease in risk (summery RR=0.62, 95%
CI: 0.49-0.79 and 0.60, 95%CI: 0.47-0.78, respectively). In secondary analyses, the association between tubal ligation
and ovarian cancer risk was stronger for endometrioid tumors (summary RR=0.45, 95%CI: 0.33, 0.61) compared to
serous tumors.
Conclusion: Observational epidemiologic evidence strongly supports that tubal ligation and hysterectomy are
associated with a decrease in the risk of ovarian cancer, by approximately 26-30%. Additional research is needed to
determine whether the association between tubal ligation and hysterectomy on ovarian cancer risk differs by
individual, surgical, and tumor characteristics.
Keywords: Ovarian neoplasms, Sterilization, Tubal, Hysterectomy
Introduction
Ovarian cancer is the fifth leading cause of cancer death
in US women [1], yet primary prevention recommenda-
tions are limited. Gynecological surgeries including tubal
ligation and hysterectomy may alter ovarian cancer risk
by protecting the ovary from ascending carcinogens or
damaging the utero-ovarian artery altering hormonal
function. In addition, tubal ligation may increase im-
munity against the surface glycoprotein human mucin 1
(MUC1) [2-4]. While tubal ligation and hysterectomy
generally have been found to be inversely associated with
ovarian cancer, effect estimates vary between studies and
little is known about potential effect modifiers of these
associations. Therefore, we conducted a meta-analysis of
the association between ovarian cancer and tubal
ligation as well as hysterectomy.
Materials and methods
Through searches in the PubMed, Web of Science, and
Embase databases, we sought to identify all English-
language articles with quantitative data on the associ-
ation between tubal ligation or hysterectomy and the
risk of ovarian cancer. Database searches encompassed
articles dated 1969 through March 2011. We identified
articles using the keywords “ovarian cancer” and “tubal
ligation” or “tubal sterilization” as well as “ovarian can-
cer” and “hysterectomy.” In addition, we reviewed the
references of selected articles to identify studies missed
through our search. We also completed a reverse
* Correspondence: nhmsr@channing.harvard.edu
1Channing Laboratory, Department of Medicine, Brigham and Women’s
Hospital and Harvard Medical School, Boston, MA, USA
2Department of Epidemiology, Harvard School of Public Health, Boston, MA,
USA
Full list of author information is available at the end of the article
© 2012 Rice; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Rice et al. Journal of Ovarian Research 2012, 5:13
http://www.ovarianresearch.com/content/5/1/13citation query to include pertinent articles, which refer-
enced those already identified, using the Cited Reference
Search application available through the Web of Science.
All articles selected for inclusion in our analyses were
verified by a second reviewer.
We abstracted relative risks (RRs) and 95% CIs or
p-values from selected articles. We used estimates
adjusted for multiple confounders when available
and calculated standard errors from the 95% CIs or
p-values. We decided apriori to use a random-effects
model to calculate the summary RR estimates and
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evaluate the consistency of findings among studies
and Begg’s and Egger’s tests were used to assess
publication bias [6,7]. We conducted meta-regression
analyses to assess whether effect estimates differed
by study design (i.e., case–control versus cohort ver-
sus other design) and by population studied (i.e.,
general population versus BRCA mutation carriers)
[8]. In secondary analyses, we conducted meta-re-
gression analyses in subsets of the studies to assess
whether the effect estimates differed by age at pro-
cedure, years since procedure, and, for the tubal
ligation analysis, by histological subtype (i.e., serous,
mucinous, endometrioid, clear cell, other). All ana-
lyses were conducted using the Stata/SE 10.0 for
Windows.
Results
Database search
We identified 30 studies that provided estimates of the
risk of ovarian cancer in relation to tubal ligation as well
as the p-value or 95% confidence interval (CI) [9-37] to in-
clude in the meta-analysis (Figure 1). One of the studies
examined the risk of ovarian cancer death [28] and three
studies were conducted in BRCA carriers [13,18,20].
Therefore, we conducted sensitivity analyses examining
the influence of these studies, which are detailed below.
For the examination of hysterectomy and ovarian cancer,
we identified 24 studies to include in the meta-analysis
(Figure 1) [9,10,12,13,15,16,23-26,29,31,32,38-47]. Nine of
the studies reported effect estimates for simple hys-
terectomy, [23,25,29,32,38,42,43,45] seven provided
estimates for hysterectomy with unilateral oophorectomy,
[23,29,32,38,42,45] and 15 did notd i s t i n g u i s hw h e t h e ro r
not women with hysterectomy underwent a unilateral oo-
phorectomy [9,10,12,13,15,16,24,26,31,39-41,44,46,47]. Two
of the studies included in the primary meta-analysis for
both tubal ligation and hysterectomy were pooled analyses
[9,31], one was comprised of eight studies [31] and another
was comprised of four studies [9]. For these studies, we
included the pooled estimates in our meta-analysis as we
were unable to obtain the study-specific effect estimates for
all studies through our literature search. One of the studies
identified in our tubal ligation and hysterectomy literature
searches was a study in the New England case–control
study (NECC) [Cramer]. However, in this study the refer-
ence category for the odds ratios for tubal ligation and hys-
terectomy was comprised of women who did not have any
pelvic surgeries, including cesarean sections. In order for
the effect estimates from the NECC to be comparable to
other studies, we requested and obtained from NECC
researchers the odds ratio for ovarian cancer comparing
women who had a tubal ligation to those who did not have
the procedure as well as the odds ratio comparing women
with hysterectomy to those who did not have a hysterec-
tomy. We also obtained odds ratios for the secondary ana-
lyses described below.
In secondary analyses, we identified studies that reported
the relative risk of ovarian cancer by characteristics of sur-
gery, such as age at or years since procedure, as well as by
histological subtype of ovarian cancer. We identified eight
studies that reported stratum-specific estimates of ovarian
cancer risk by years since tubal ligation (Additional file 1:
Table S1) [14,19,25,26,28,29,48] and nine studies that
reported stratum-specific estimates for age at tubal ligation
(Additional file 1: Table S2) [13,14,19,25,27-29,48]. In
addition, 13 studies specified effect estimates for invasive
ovarian cancer [10,12,15,17-23,31,33] and 11 studies on
tubal ligation reported estimates for at least one histological
subtype of ovarian cancer (Additional file 1: Table S3)
[9,10,15,16,19,22,24,26,29,49]. Eight studies on hysterec-
tomy reported stratum-specific estimates of ovarian cancer
risk by years since the procedure (Additional file 1: Table
S4) [25,26,29,31,43,45,46] and five studies reported
stratum-specific estimates for age at hysterectomy
(Additional file 1: Table S5) [25,29,31,43]. In addition, nine
studies reported effect estimates for invasive ovarian can-
cer [[10,12,15,23,31,40-42], Cramer].
Separate analyses were performed examining risk of
ovarian cancer and characteristics of surgery, including
years since and age at procedure. For six of the eight
studies reporting stratum-specific estimates for years
since tubal ligation, we were able to derive estimates for
less than 10 years since tubal ligation and 10 or more
years since tubal ligation [19,25,26,29,48]. For seven of
the nine studies that reported risks by age at tubal
ligation, we were able to derive estimates for age less
than 35 at tubal ligation and 35 years of age or older
[13,19,27-29,48]. For seven of the eight studies reporting
stratum-specific estimates for years since hysterectomy,
we were able to derive estimates for less than 10 years
since hysterectomy and 10 or more years since hysterec-
tomy [22,25,26,31,43,45]. For the five studies that
reported risks by age at hysterectomy, we were able to
derive estimates for age less than 40 or 45 at hysterec-
tomy and 40 or 45 years of age or older [25,29,31,43]
[NECC].
Rice et al. Journal of Ovarian Research 2012, 5:13 Page 2 of 16
http://www.ovarianresearch.com/content/5/1/13Tubal ligation
The estimated RRs for ovarian cancer associated with
tubal ligation versus no tubal ligation ranged from 0.2 to
2.4 (Table 1). Twenty-seven of the 30 studies reported
lower risks of ovarian cancer in women who had a tubal
ligation compared to those who had not had the proced-
ure. The three studies that observed an elevated risk of
ovarian cancer did not achieve statistical significance
[14,16,35]. The summary RR was 0.70 (95%CI: 0.64,
0.75), demonstrating a statistically significant inverse as-
sociation between tubal ligation and ovarian cancer
(Figure 2). Some studies in our analysis did not specify
whether borderline cases were included in the analyses.
However, when we restricted our analysis to 13 studies
that reported the association for invasive ovarian cancer,
specifically the summary RR was very similar (summary
RR=0.72; 95%CI: 0.66, 0.72). Since there was evidence
of heterogeneity among the 30 studies (P=0.02), we
examined the contribution of study characteristics to the
heterogeneity. We did not observe statistically significant
evidence of heterogeneity by study design (i.e., cohort
study, case–control study, or other) or residence of study
Tubal Ligation Literature search (N=179) 
   Databases: PubMed, Embase, Web of Science 
   Limits: English 
   Search terms: “tubal sterilization” and “ovarian cancer”; “tubal ligation” and “ovarian cancer” 
Reference search and reverse citation (N=3) 
   Database:  Web of Science (Cited Reference Search) 
Hysterectomy literature search (N=4) 
Hysterectomy Literature search (N=5,727) 
   Databases: PubMed (N=2,051), Embase (N=2,698), Web of Science (N=978) 
   Limits: Human, Female, Cancer, English 
   Search terms: “hysterectomy” and “ovarian cancer” 
Reference search and reverse citation (N=18) 
   Database:  Web of Science (Cited Reference Search) 
Tubal ligation literature search (N=5) 
Personal communication with NECC researchers (N=1) 
Title and abstract screened 
Excluded (n=5,666) 
Did not present original data on
hysterectomy and ovarian cancer 
(review articles, hysterectomy 
was a stratification variable, etc.) 
Included (N=85)
Manuscript review 
Excluded (N=14) 
Participants overlapped with 
included study/later publication 
available: 13 
Tubal sterilization and 
hysterectomy combined 
exposure: 1 
Included (N=30) 
Tubal ligation study selection 
Search results combined (N=187) 
Hysterectomy study selection 
Search results combined (N=5,751) 
Title and abstract screened 
Excluded (n=143) 
Did not present original data on 
tubal sterilization and ovarian 
cancer (review articles, 
sterilization was a stratification 
variable, etc.) 
Included (N=44)
Manuscript review 
Excluded (N=61) 
Participants overlapped with
included study/later publication 
available: 39 
   Case only data available: 12 
   Poorly defined exposure: 10 
Included (N=24) 
Figure 1 Selection of studies on tubal ligation and hysterectomy with risk of ovarian cancer.
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Author (Country) Study Design Case definition Covariates OR, RR, or SIR (95%CI) Comments
NECC 2012 (USA)
[personal
communication
with Dr. Daniel
Cramer]
Case-control Borderline or invasive
epithelial ovarian cancer
N=2076
age, study center, BMI , study phase, smoking,
family history of ovarian and breast cancers,
talc use, OC use, parity, breast feeding, age at
menarche, post-menopausal status, use of
post-menopausal hormones, hysterectomy
0.79 (0.66-0.94)
Ness et al. 2011
(USA) [11]
Case-control Invasive or borderline
epithelial ovarian cancer
Age, number of pregnancies, race, infertility,
family history of
0.63 (0.51-0.77)
N=867 ovarian cancer, ever use of oral contraceptives,
ever use of IUDs, ever use of barriers,
vasectomy
Moorman et al.
2009 (USA) [12]
Case-control North
Carolina Ovarian Cancer
Study
Invasive epithelial ovarian
cancer
Age, parity, age at menarche, duration of OC
use, family history of breast/ovarian cancer,
BMI
Whites: 0.74 (0.58, 0.94)
African-Americans: 0.43 (0.24,
0.80) N=746 White cases
N=111 African-American
cases
Antoniou et al.
2009 (Europe and
Canada) [13]
Retrospective Cohort Ovarian cancer (only BRCA 1/
2 carriers)
Age, duration of OC use, parity BRCA 1/2: 0.43 (0.24, 0.75) Includes prevalent and incident
cases.
BRCA1: 0.42 (0.22, 0.80)
N=201 BRCA1 cases
BRCA2: 0.47 (0.18, 1.21) Mean difference between age at
diagnosis and interview: 6.7 years N=52 BRCA2 cases
Wu et al. 2009
(USA) [37]
Case-control Invasive and borderline
ovarian cancer
Race/ethnicity, age, education, family history
of ovarian cancer, menopausal status, use of
oral contraceptives, parity
0.66 (0.47, 0.93)
N=609 cases
Dorjgochoo T.
et al. 2009 (China)
[14]
Prospective cohort Ovarian cancer Age, education, age at menarche, parity,
breastfeeding, BMI, physical activity, smoking,
menopausal status, family history of cancer,
other contraceptive methods.
1.17 (0.62, 2.26) Cohort N=66,661
N=94 cases 76.1% participation rate
Nagle et al. 2008
(Australia) [15]
Case-control Invasive epithelial
endometrioid and clear cell
ovarian cancer
Age, education, parity, and hormone
contraceptive use
Endometrioid: 0.4 (0.3, 0.7) 47% participation rate in controls
Clear cell: 0.7 (0.4, 1.2)
N=142 endometrioid cases
N=90 clear cell cases
Jordan et al. 2008
(Australia) [10]
Case-control Invasive epithelial serous
ovarian cancer
Parity, hormonal contraceptive use, history of
breast or ovarian cancer, age, education
Serous (invasive): 0.87 (0.69-
1.09)
N=627 cases
Jordan et al. 2007
(Australia) [16]
Case-control Epithelial benign serous
tumors (N=230) and benign
mucinous tumors (N=133)
Age, state of residence, education, parity,
hormonal contraceptive use, hysterectomy,
smoking status
Combined: 1.04 (0.76-1.44) 65% participation rate in cases,
47% in controls.
Mucinous: 1.00 (0.61-1.64)
Serous: 1.08 (0.75-1.57)
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3Table 1 Epidemiologic Studies of the Association Between Tubal Ligation and Risk of Ovarian Cancer (Continued)
Tworoger et al.
2007 (USA) [17]
Prospective cohort Incident invasive epithelial
ovarian cancer
Age, BMI, parity, smoking history, age at
menarche, age at menopause, duration of
postmenopausal hormone use, duration of
oral contraceptive use
0.66 (0.50, 0.87) Update of Hankinson et al. 1993
N=612 cases
McLaughlin JR
et al. 2007
(International) [18]
Case-control Invasive ovarian cancer (only
BRCA 1/2 carriers)
Age, mutation type, country of residence,
parity, breastfeeding, oral contraceptive use,
ethnicity.
BRCA1+2 carriers: 0.78 (0.60,
1.00)
Includes prevalent and incident
cases. Results similar when
restricted to women interviewed
within 3 years of diagnosis. BRCA1: 0.80 (0.59, 1.08)
N=799 cases BRCA2: 0.63 (0.34, 1.15)
BRCA1 N=670 BRCA2 N=128
BRCA1/2 N=1
Modugno et al.
2004 (USA) [9]
Pooled case-control Epithelial ovarian cancer Study site, age, family history, duration of oral
contraceptive use, parity
0.63 (0.54, 0.73) Pooled analysis from four studies.
N=2098 cases
Kjaer et al. 2004
(Denmark) [19]
Population-based follow-
up study
Invasive ovarian cancer and
borderline ovarian tumor
Age and calendar year Invasive: 0.82 (0.6, 1.0) Observed number of cancer
cases in cohort of women who
underwent tubal ligation was
compared to the expected
number of cases based on the
age and calendar year specific
rates from the Danish Cancer
Registry.
Borderline: 0.82 (0.5, 1.3)
N=75 invasive cases
N=21 borderline cases
McGuire et al.
2004 (USA) [20]
Case-control Invasive epithelial ovarian
cancer
Age, parity, duration of OC use, race/ethnicity BRCA 1 carriers: 0.68 (0.25,
1.90)
Noncarriers: 0.65 (0.45, 0.95) N=36 BRCA1 cases
N=381 noncarrier cases
Pike et al. 2004
(Los Angeles, USA)
[21]
Case-control Invasive ovarian cancer Age, ethnicity, SES, education, family history of
ovarian cancer, use of talc, BMI, parity, age at
last birth, number of incomplete pregnancies,
OC use, menopausal status, age at
menopause, hormone replacement therapy
0.82 (0.53-1.26)
N=477 cases
Rutter et al. 2003
(Israel) [23]
Case-control Invasive epithelial ovarian
cancer or primary peritoneal
cancer
Age, ethnicity, parity, years of oral
contraceptive use
0.70 (0.42, 1.18) Participation rate was 79% for
case patients and 66% for
controls.
N=1124 cases
Wittenberg et al.
1999 (USA) [24]
Case-control Mucinous and non-mucinous
epithelial ovarian cancer
Age at diagnosis, parity, duration of OC use Mucinous: 0.4 (0.1, 1.9) 64% participation rate in cases,
72% in controls. Included both
borderline and invasive. Non-mucinous: 0.6 (0.3, 1.1)
N=43 mucinous cases
N=279 non-mucinous cases
Kreiger et al, 1997
(Canada) [25]
Historical cohort study Invasive and borderline
ovarian cancer
Age, calendar year, length of follow-up 0.57 p<0.001 Calculated observed over
expected events.
N=108 observed cases in
tubal ligation subcohort
Sensitivity analysis excluding
borderline malignancies similar.
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3Table 1 Epidemiologic Studies of the Association Between Tubal Ligation and Risk of Ovarian Cancer (Continued)
Green, Purdie,
et al. 1997
(Australia) [26]
Case-control Incident, primary epithelial
ovarian cancer
Age, education, BMI, parity, OC duration,
smoking, family history of ovarian cancer
0.61 (0.46, 0.85) 90% participation rate in cases,
73% in controls.
N=824 cases
Cornelison et al
1997 (USA) [27]
Case-control Ovarian cancer N=300 cases Age , SES, marital status, parity, age at first
pregnancy, age at menarche, age at
menopause, irregular menses, breast-feeding
duration, BMI, OC use
0.52 (0.31,0.85) Patient controls with no
malignancy or ovarian disease.
Miracle-McMahill,
et al. 1997 (USA)
[28]
Prospective Cohort Study Ovarian cancer mortality Age, race, BMI, education, family history of
ovarian cancer, family history of breast ca,
parity, marital status, age at menarche, OC
use, ERT, age at menopause, miscarriages
smoking status
0.68 (0.45, 1.03)
N=799 ovarian cancer deaths
Rosenblatt, et al.
1996
(International) [29]
Case-control Borderline or malignant
epithelial ovarian cancer
Age, hospital, year of interview, parity OC use 0.71 (0.47, 1.08) No differences observed for
borderline and malignant
tumors.
N=385 cases
Risch et al. 1996
(Canada) [22]
Case-control Epithelial ovarian cancer Age, parity, years of OC use, average lactation/
pregnancy, total years of ERT, hysterectomy,
family history of breast cancer
0.67 (0.47-0.94) Invasive and borderline tumors
included.
N=450 cases Borderline
N=83 Invasive N=376
Nandakumar et al.
1995 (India) [30]
Case-control Ovarian cancer Age, residential area, parity, age at first birth 0.25 (0.08, 0.78) Restricted to ever-married
women. Hospital-based controls.
N=97 cases
Whittemore et al
1992 (USA) [31]
Pooled case-control Invasive epithelial ovarian
cancer
Age, study, parity, OC use Hospital-based studies: Restricted to white women. 6
hospital based studies and 6
population-based studies. 0.59 (0.38, 0.93) Population-
based studies: 0.87 (0.62, 1.20)
N=2197 cases
Booth et al 1989
(England) [32]
Case-control Epithelial ovarian cancer Age, social class, gravidity, unprotected
intercourse
0.2 (0.1, 0.6) Cases were less than 65 years old
and interviewed within 2 years of
diagnosis. Age-matched hospital-
based controls.
N=235 cases
Shu et al 1989
(China) [33]
Case-control Invasive epithelial ovarian
cancer
Age, education, parity, age at menarche,
ovarian cyst
0.8 (0.4, 1.6) 89% participation rate in cases,
100% in controls. All <70 years
of age.
N=172 cases
Koch et al 1988
(Canada) [34]
Case-control Epithelial ovarian cancer None 0.8 (0.5, 1.3) 47% participation rate in controls.
Age-matched, but did not
control for age in analyses. N=200 cases
Mori et al 1988
(Japan) [36]
Case-control Primary epithelial ovarian
cancer
Age, parity, marital status, number of induced
abortions
0.5 (0.25, 1.00) Controls were hospital in-patients
with gynecological complaints
other than ovarian cancer and
OB/GYN outpatients without a
malignant ovarian disorder.
100% participation rate in cases
and controls.
N=110 cases
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3Table 1 Epidemiologic Studies of the Association Between Tubal Ligation and Risk of Ovarian Cancer (Continued)
Koch et al. 1984
(Canada) [35]
Retrospective cohort Ovarian cancer N=4 cases Age, nulliparity 2.4 (0.9, 6.7) Population who underwent tubal
ligation were mental patients.
34% were lost to follow-up.
Many underwent the procedure
at young ages (i.e. 10-19).
Expected rates calculated from a
previous retrospective study.
Incomplete adjustment for parity.
Abbreviations: OR, odds ratio; RR, relative risk; SIR, standardized incidence ratio; OC, oral contraceptive; BMI, body mass index; SES, socio-economic status; ERT, estrogen replacement therapy.
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3participants (i.e., USA or non-USA) (P>0.05) (Table 2).
Interestingly, the relative risk among BRCA carriers
(RR=0.64, 95%CI: 0.43-0.96) was similar to the relative
risk among population-based studies (RR=0.70, 95%CI:
0.64-0.76) (Table 2). Overall, we found that if any single
study was removed from the meta-analysis, the effect es-
timate did not change substantially (data not shown). In
addition, we found no evidence of publication bias using
either the Begg (P=0.12) or the Egger (P=0.22) method
for assessing bias.
Eight of the studies examined years since tubal
ligation. In a meta-regression of six of these studies, we
did not observe a difference in the relative risk of ovar-
ian cancer between women who had a tubal ligation less
than 10 years ago (summary RR=0.69, 95%CI: 0.59,
0.79) and those women who had a tubal ligation 10 or
more years ago (summary RR=0.68, 95%CI: 0.54, 0.87)
(P-heterogeneity=0.78) (Table 2). Of the other studies, a
prospective cohort study of ovarian cancer mortality
reported tubal ligation to be associated with a reduced
risk for women who had the procedure within 20 years,
with a smaller non-significant reduced risk for those
who had the procedure 20 or more years ago.[19] How-
ever, a prospective cohort study based in China observed
a non-significant increase in risk that was similar for
both women who had a tubal ligation less than 33 years
ago and women who had a tubal ligation 33 or more
years ago [14].
Figure 2 Forest plot for 30 studies of the association between tubal ligation and ovarian cancer risk. Forest plot summarizing individual
effect estimates from 30 studies [9-37] contributing to summary effect estimates describing the association between tubal ligation and ovarian
cancer risk. Black boxes mark the effect estimate for individual studies and the size of the black boxes represent the weight of individual studies
in the summary estimate; horizontal gray lines demonstrate the width of the 95%CIs associated with each individual study; the black diamonds
represent summary effect estimates; stars indicate pooled studies.
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cancer risk. In a meta-regression of seven of these studies,
the relative risk for ovarian cancer was non-significantly
lower among women who had a tubal ligation when they
were younger than 35 (summary RR=0.69, 95%CI: 0.59,
0.81) compared to at 35 years of age or older (summary
RR=0.79, 95%CI: 0.68, 0.92), although the difference was
not statistically significant (P-for-heterogeneity=0.22)
(Table 2). In addition, the Shanghai Women’sH e a l t h
Study noted a non-significant increase in ovarian cancer
risk only among women who were less than 30 when they
underwent the procedure and no association among those
aged 30 or more at time of surgery [14]. In a historical co-
hort study, tubal ligation was associated with a reduced
risk of ovarian cancer among women aged 25–44 at time
of the procedure (RR=0.54, p<0.001), but not among
women aged 45–64 at the time of their tubal ligation
(RR=1.18, p=0.68) [25].
Eleven studies reported effect estimates by at least one
histologic subtype. In a meta-analysis regression we
observed that the association was stronger for endome-
trioid tumors compared to serous tumors (P<0.01).
The summary RR for serous tumors was 0.75 (95%CI:
0.65, 0.88) compared to 0.45 (95%CI: 0.33, 0.61) for
endometrioid tumors. The summary RRs for mucinous
(summary RR=0.88, 95%CI: 0.70,1.09), clear cell (sum-
mary RR=0.72, 95%CI: 0.55, 0.94), and other tumor
types (summary RR=0.80, 95%CI: 0.63,1.01) did not sig-
nificantly differ from serous tumors (p>0.05).
Hysterectomy
The study-specific RRs for ovarian cancer associated
with hysterectomy (with or without unilateral oophorec-
tomy) ranged from 0.06 to 1.91 (Table 3). The summary
RR was 0.74 (95%CI: 0.65, 0.84), demonstrating a statisti-
cally significant inverse association between hysterec-
tomy and ovarian cancer (Figure 3). When we restricted
to nine studies that reported effect estimates for invasive
ovarian cancer, the association was similar (summary
RR=0.81; 95%CI: 0.68, 0.97). We also calculated sum-
mary estimates for simple hysterectomy and hysterec-
tomy with unilateral oophorectomy (Table 4). We
observed that the reduced risk of ovarian cancer asso-
ciated with hysterectomy with unilateral oophorectomy
(RR=0.60, 95%CI: 0.47-0.78) was similar to the reduced
risk associated with simple hysterectomy (RR=0.62, 95%
CI: 0.49-0.79). We examined the contribution of other
study characteristics to the heterogeneity between stud-
ies, since the p-heterogeneity <0.01. We did not observe
evidence for statistically significant heterogeneity by
study type (i.e., case–control, cohort, other) or geo-
graphic location (i.e., USA vs non-USA) (P>0.05)
(Table 4). Overall, if any single study was removed from
the meta-analysis, the effect estimate did not change
substantially (data not shown). We did note evidence of
publication bias using the Egger (P=0.01) method for
assessing bias, but not for the Begg method (P=0.11).
Eight studies examined years since hysterectomy and
ovarian cancer risk. In a meta-regression of seven of
these studies, the RR of ovarian cancer between women
who had the procedure 10 or more years ago was
slightly lower compared to women who had a hysterec-
tomy less than 10 years ago (summary RR=0.69, 95%
CI: 0.60, 0.79 and summary RR=0.77, 95%CI: 0.66,
0.89 respectively) (P-heterogeneity=0.33). In addition,
ah o s p i t a l - b a s e dc a s e –control study reported an in-
verse association among women who underwent the
procedure more than five years ago (RR=0.37, 95%CI:
0.11-1.24), but no association among those who had a
hysterectomy within five years (RR=1.04, 95%CI:
0.37-2.90) [29]. Five studies examined age at hysterec-
tomy on ovarian cancer risk, three dichotomized at
age 40 and two at age 45. In a meta-regression, hys-
terectomy was more strongly inversely associated with
ovarian cancer among women who were younger than
40 or 45 at surgery compared to 40 or 45 years of
age or older, however the p for heterogeneity was not
Table 2 Summary relative risks for tubal ligation and
ovarian cancer by selected characteristics
Number of
contributing studies
Random-effects
RR (95%CI)
Study design 30 studies
Cohort study 0.67 (0.50, 0.90)
Case-control study 0.70 (0.63, 0.75)
Other study design 0.95 (0.63, 1.43)
BRCA status 30 studies
BRCA positive 0.64 (0.43, 0.96)
General population 0.70 (0.64, 0.76)
Geographic location 30 studies
US 0.68 (0.63, 0.73)
Non-US 0.71 (0.61, 0.82)
Histologic subtype 11 studies
Serous 0.75 (0.65,0.88)
Endometrioid 0.45 (0.33,0.61)
Mucinous 0.88 (0.70,1.09)
Clear cell 0.72 (0.55,0.94)
Other 0.80 (0.63,1.01)
Age at tubal ligation 7 studies
<35 years of age 0.69 (0.59,0.81)
35+ years of age 0.79 (0.68,0.92)
Years since tubal ligation 6 studies
<10 years 0.69 (0.59,0.79)
10+ years 0.68 (0.54,0.87)
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http://www.ovarianresearch.com/content/5/1/13Table 3 Epidemiologic Studies of the Association Between Hysterectomy and Risk of Ovarian Cancer
Author (Country) Study Design Case definition Covariates OR, RR, or SIR (95%CI) Comments
NECC 2012 (USA)
[Personal
communication
with Dr. Daniel
Cramer]
Case-control Borderline and invasive ovarian
cancer
age, study center, BMI , study phase,
smoking, family history of ovarian and
breast cancers, talc use, OC use , parity,
breast feeding, age at menarche, post-
menopausal status, use of post-menopausal
hormones, tubal ligation
Hysterectomy only: 1.10 (0.83-1.46) NECC 2012 (USA) [Personal
communication with Dr. Daniel
Cramer]
N=2076 Hysterectomy with unilateral
oophorectomy: 0.68 (0.46-0.99)
Annegers et al.
1979 (USA) [38]
Case-control
(Rochester Project)
Epithelial ovarian cancer N=116
cases
Controls matched on age and residence Hysterectomy only: 0.36 (0.10-0.73)
Hysterectomy with unilateral
oophorectomy: 0.06 (0.004-0.98)
Antoniou et al.
2009 (Europe and
Canada) [13]
Retrospective Cohort Ovarian cancer (only BRCA 1/2
carriers)
Age, duration of OC use, parity Hysterectomy with or without
unilateral oophorectomy: BRCA 1/2:
0.59 (0.22, 1.57)
Includes prevalent and incident
cases.
N=201 BRCA1 cases Mean difference between age at
diagnosis and interview: 6.7 years
N=52 BRCA2 cases BRCA1:0.68 (0.22, 2.12)
BRCA2: 0.35 (0.08, 1.58)
Beard et al. 2000
(USA) [40]
Case-control
(Rochester Project)
Invasive epithelial ovarian cancer Controls matched on age and provider Hysterectomy with or without
unilateral oophorectomy: 0.5
(0.2–0.96) N=103 cases
Booth et al 1989
(England) [32]
Case-control Epithelial ovarian cancer Age and social class Hysterectomy only: 0.2 (0.1-0.4) Cases less than 65 years old and
diagnosed within 2 years. Age-
matched hospital-based controls. N=235 cases Hysterectomy with unilateral
oophorectomy: 0.4 (0.1-1.1)
Braem et al. 2010
(Netherlands) [41]
Case-cohort study
(Netherlands Cohort
Study)
Invasive epithelial ovarian cancer Age, OC use, parity Hysterectomy with or without
unilateral oophorectomy: 0.50
(0.34-0.72)
All women presumed to be
postmenopausal
N=375
Chiaffarino et al.
2005 (Italy) [42]
Multi-center case-
control study
Incident invasive epithelial
ovarian cancer
Age, center, education, parity, OC use, family
history of ovarian and breast cancer
Hysterectomy only: 0.6 (0.4-0.9)
Hysterectomy and unilateral
oophorectomy: 0.6 (0.3-1.1)
N=1031 cases
Green, Purdie,
et al. 1997
(Australia) [26]
Case-control Incident, primary epithelial
ovarian cancer
Age, education, BMI, parity, OC duration,
smoking, family history of ovarian cancer
Hysterectomy with or without
unilateral oophorectomy: 0.64
(0.48-0.85)
90% participation rate in cases, 73%
in controls.
N=824 cases
Hankinson et al.
1993 (USA) [43]
Cohort study (NHS) Borderline and malignant
epithelial ovarian cancer
Age, parity, duration of OC use, age at
menarche, tubal ligation, smoking status,
BMI
Hysterectomy only: 0.67 (0.45-1.00) 90% follow-up rate
N=260 cases
Jordan et al. 2008
(Australia) [10]
Case-control Invasive epithelial serous ovarian
cancer
Parity, hormonal contraceptive use, history
of breast or ovarian cancer, age, education
Hysterectomy with or without
unilateral oophorectomy:
N=627 cases Serous (invasive): 1.27 (1.00, 1.60)
Jordan et al. 2007
(Australia) [16]
Case-control Benign serous tumors (N=230)
and benign mucinous tumors
(N=133)
Age, state of residence, education, parity,
hormonal contraceptive use, smoking status
Hysterectomy with or without
unilateral oophorectomy:
65% participation rate in cases, 47%
in controls.
Combined: 1.91 (1.38-2.66)
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3Table 3 Epidemiologic Studies of the Association Between Hysterectomy and Risk of Ovarian Cancer (Continued)
For serous tumors by surgical
indication:
Mucinous: 0.95 (0.55-1.67) Non-hormonal: 1.1 (0.5-2.7)
Serous: 2.75 (1.90-3.96) Hormonal: 3.0 (2.1-4.5)
Kreiger et al. 1997
(Canada) [25]
Historical cohort study Ovarian cancer N=169 observed
cases in hysterectomy subcohort
Age, calendar year, length of follow-up Hysterectomy only: 0.72 p<0.001 Calculated observed over expected
events.
Sensitivity analysis excluding
borderline malignancies similar.
Loft et al. 1997
(Denmark) [44]
Prospective historical
cohort study
Ovarian cancer Age Hysterectomy with and without
unilateral oophorectomy: 0.78
(0.60-0.96)
N=22,135 women w/ hysterectomy
(3940 of whom had unilateral
oophorectomy) N=71
Follow-up=12.5 years
Luoto et al. 1997
(Finland) [39]
Historical cohort study Ovarian cancer Adjusted for education, parity, and follow-
up. Non-hysterectomized women had
similar distributions of age and municipality.
Partial hysterectomy: RR=0.94
(0.68-1.30)
Ovarian status not assessed.
N=53 cases with partial
hysterectomy
N=91 cases with total
hysterectomy
Total hysterectomy: RR=0.62
(0.48-0.80)
Modugno et al.
2004 (USA) [9]
Pooled case-control Epithelial ovarian cancer Study site, age, family history, duration of
oral contraceptive use, parity, endometriosis,
tubal ligation
Hysterectomy with or without
unilateral oophorectomy: 0.99
(0.83-1.18)
Pooled analysis from four studies.
N=2098 cases Analyzed by endometriosis status.
Moorman et al.
2009 (USA) [12]
Case-control North
Carolina Ovarian
Cancer Study
Invasive epithelial ovarian cancer Age, parity, age at menarche, duration of
OC use, family history of breast/ovarian
cancer, BMI
Hysterectomy with or without
unilateral oophorectomy:
N=746 White cases
N=111 African-Am cases Whites: 1.22 (0.97, 1.54) African-
Americans: 1.07 (0.61, 1.87)
Nagle et al. 2008
(Australia) [15]
Case-control Invasive epithelial endometrioid
and clear cell ovarian cancer
Age, education, parity, and hormone
contraceptive use
Hysterectomy with or without
unilateral oophorectomy:
47% participation rate in controls
N=142 endometrioid cases Endometrioid: 1.2 (0.8, 1.9)
Clear cell: 0.9 (0.5, 1.6) N=90 clear cell cases
Parazzini et al.
1993 (Italy) [45]
Case-control study Epithelial ovarian cancer Age, education, parity, oral contraceptive
use, menarche, menopause
Hysterectomy only: 0.6 (0.5-0.9)
N=953 cases Hysterectomy with unilateral
oophorectomy: 0.6 (0.3-1.3)
Risch et al. 1994
(Canada) [46]
Case-control Epithelial ovarian cancer Age, duration of OC use, number of full-
term pregnancies
Hysterectomy with or without
unilateral oophorectomy: 0.51
(0.36-0.72) N=450 cases
Rosenblatt et al.
1996 (Multi-
national) [29]
Case-control (Multi-
site/country)
Borderline or invasive epithelial
ovarian cancer
Age, date of diagnosis, center, parity, OC use Hysterectomy only: 0.41 (0.14-1.21)
N=385 cases
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3Table 3 Epidemiologic Studies of the Association Between Hysterectomy and Risk of Ovarian Cancer (Continued)
Hysterectomy with unilateral
oophorectomy: 1.06 (0.34-3.29)
Combined: 0.58 (0.27-1.28)
Rutter et al. 2003
(Israel) [23]
Case-control Epithelial ovarian cancer or
primary peritoneal cancer
Age, ethnicity, parity, years of oral
contraceptive use
Hysterectomy only: 0.69 (0.50-0.95) Participation rate was 79% for case
patients and 66% for controls.
Includes BRCA-specific analysis.
N=1124 cases Hysterectomy with unilateral
oophorectomy: 0.46 (0.25-0.86)
Whittemore et al
1992 (USA) [31]
Pooled case-control
(12 studies included)
Invasive epithelial ovarian cancer Age, study, parity, OC use Hysterectomy with or without
unilateral oophorectomy: Hospital-
based studies: 0.66 (0.50-0.86)
Restricted to white women. 6
hospital based studies and 6
population-based studies. All
hysterectomies performed at least 2
years prior to reference date.
N=2197 cases
Population-based studies: 0.88
(0.72-1.1)
Wittenberg et al.
1999 (USA) [24]
Case-control Mucinous and non-mucinous
epithelial ovarian cancer
Age at diagnosis, parity, duration of OC use Hysterectomy with or without
unilateral oophorectomy: Mucinous:
0.2 (0.1, 1.0)
64% participation rate in cases, 72%
in controls. Included both
borderline and invasive.
N=43 mucinous cases
N=279 non-mucinous cases Non-mucinous: 1.1 (0.7, 1.6)
Wynder et al.
1969 (USA) [47]
Case-control (Hospital
based)
Epithelial ovarian cancer (N=150)
plus miscellaneous ovarian
tumors (N=8)
Age-matched controls Hysterectomy with or without
unilateral oophorectomy: 0.7
(0.04-1.0)
Abbreviations: OR, odds ratio; RR, relative risk; SIR, standardized incidence ratio; OC, oral contraceptive; BMI, body mass index; SES, socio-economic status.
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3statistically significant (P-heterogeneity=0.29). The
summary RR for women less than 40 or 45 years of
age was 0.70 (95%CI: 0.55, 0.89) compared to 0.83
(95%CI: 0.72, 0.96) for women over 40 or 45 years of
a g e( T a b l e4 ) .
Discussion
Observational epidemiologic evidence strongly suggests
that there is a decreased risk of ovarian cancer among
women who have had a tubal ligation or hysterectomy.
We observed an approximately 26-30% reduction in
ovarian cancer risk among women who had a tubal
ligation or hysterectomy compared to women who never
had a tubal ligation or hysterectomy, respectively. These
estimates did not vary substantially by study design or
population. We did not observe any significant differ-
ences in the effect estimates by years since procedure.
For both hysterectomy and tubal ligation, the inverse as-
sociation between these procedures and ovarian cancer
risk was suggestively stronger among women who
underwent the procedure at earlier ages. There was
evidence that tubal ligation may be associated with a
stronger reduced risk for endometrioid tumors com-
pared to serous tumors; however this finding was
based on studies with small numbers of cases of each
subtype and should be interpreted cautiously.
Several mechanisms have been proposed to explain
the observed inverse association between tubal ligation
and hysterectomy and ovarian cancer risk. One potential
explanation is a “screening effect” wherein surgeons are
Figure 3 Forest plot for 24 studies of the association between hysterectomy and ovarian cancer risk. Forest plot summarizing individual
effect estimates from 24 studies [9,10,12,13,15,16,23,26,29,31,32,38-47] contributing to summary effect estimates describing the association
between hysterectomy and ovarian cancer risk. Black boxes mark the effect estimate for individual studies and the size of the black boxes
represent the weight of individual studies in the summary estimate; horizontal gray lines demonstrate the width of the 95% CIs associated with
each individual study; the black diamonds represent summary effect; stars indicate pooled studies. HUO=hysterectomy with unilateral
oophorectomy, SH=simple hysterectomy, UH=unknown type of hysterectomy.
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http://www.ovarianresearch.com/content/5/1/13able to visualize abnormal changes in the ovaries during
tubal sterilizations or hysterectomies and remove pre-
malignant lesions. If the inverse association was solely
due to screening of the ovaries, these procedures would
be associated with a lower risk for only a few years after
the surgery; however this was not supported in our ana-
lysis as there was a strong inverse association even more
than 10 years after surgery. Another potential mechan-
ism is that tubal ligation and hysterectomy protect the
ovary from carcinogens, such as talc, or inflammatory
agents such as retrograde menstruation or endometriosis
ascending the genital tract. Green et al. reported that
ovarian cancer risk was highest among women who used
talc and did not have a tubal ligation or hysterectomy
and lowest among women who had surgical sterilization,
but did not use talc [26]. However, in the Nurses’ Health
Study (NHS), there was no variation in RR estimates of
tubal ligation and ovarian cancer by talc use, and in a
large case–control study, the inverse association of tubal
ligation and hysterectomy was limited to non-talc users,
contrary to the ascending carcinogen hypothesis [43,50].
Ovarian cancer risk may be altered by decreased blood
supply to the ovary after surgery resulting in a decrease
in estrogen production. However, while some studies
have observed decreases in hormone levels after tubal
ligation or hysterectomy, [51-53] others have not
[54,55]. This mechanism may only apply to procedures
that cause substantial damage to the surrounding tissue.
In the NHS, women who had undergone tubal ligation
during the time period when the unipolar electrocautery
method was commonly used had a reduced risk of
breast cancer [56]. However, tubal ligation was not asso-
ciated with breast cancer risk during other periods when
methods that caused less tissue destruction were com-
mon. To our knowledge, only one study examined ovar-
ian cancer risk by type of tubal ligation and observed a
lower risk irrespective of technique [26]. However this
analysis was based on only 20 cases and 58 controls and
thus had limited power. Lastly, several cancers, including
ovarian cancers, over-express the surface glycoprotein
MUC1. It has been hypothesized that women who have
undergone events that trigger an immune response to
MUC1 have a decreased risk of ovarian cancer [4]. A re-
cent study reported higher anti-MUC1 antibodies were
associated with a decreased risk of ovarian cancer
among women less than 64 years of age [57]. In the
same study, women who had undergone a tubal ligation
had higher mean levels of anti-MUC1 antibodies com-
pared to women who had not undergone a tubal
ligation; however there were no differences in antibodies
levels by hysterectomy status [57]. Further research is
needed to determine the associations between surgical
procedures, anti-MUC1 antibodies, and subsequent
ovarian cancer risk.
Our analysis has several limitations. Not all studies
reported whether cases were restricted to invasive ovar-
ian cancer., however when we restricted to studies that
reported effect estimates for invasive ovarian cancer the
summary RRs were very similar. Few studies reported ef-
fect estimates by surgical characteristics or histological
subtype of ovarian cancer. In addition, when reported,
these stratum-specific estimates were often based on
small numbers of exposed cases. To pool effect estimates
for analysis of age at and years since tubal ligation, we
created very broad categories (e.g., age at tubal ligation
<35 years, ≥35 years; hysterectomy <10 years ago,
≥10 years ago), which may obscure important effects.
Some of the studies in the meta-analysis included both
prevalent as well as incident ovarian cancer cases and
the case definition for one study was ovarian cancer
mortality. If tubal ligation or hysterectomy were asso-
ciated with survival after ovarian cancer diagnosis then
the inclusion of prevalent cases may bias the effect esti-
mates. However, a recent systematic review did not sup-
port an association between tubal ligation or
hysterectomy and survival from ovarian cancer [58].
In summary, we observed a consistent inverse associ-
ation of tubal ligation and hysterectomy on ovarian cancer
risk that may be causal. We did not detect differences by
study design, study population, or years since the proced-
ure, although our statistical power in these analyses was
somewhat limited. While gynecologic surgery may be a
potential prevention strategy for women at high risk of
ovarian cancer, additional research is needed to determine
Table 4 Summary relative risks for hysterectomy and
ovarian cancer by selected characteristics
Number of
contributing studies
Random-effects
RR (95%CI)
Study design 24 studies
Cohort study 0.73 (0.63, 0.85)
Case-control study 0.73 (0.62, 0.86)
Geographic location 24 studies
US 0.81 (0.67, 0.97)
Non-US 0.70 (0.59, 0.84)
Type of hysterectomy 24 studies
With unilateral oophorectomy 0.60 (0.47, 0.78)
Without oophorectomy 0.62 (0.49, 0.79)
Unknown oophorectomy 0.83 (0.71, 0.98)
Age at hysterectomy 5 studies
<40/45 years of age 0.70 (0.55, 0.89)
40/45+ years of age 0.83 (0.72, 0.96)
Years since hysterectomy 7 studies
<10 years 0.69 (0.60, 0.79)
10+ years 0.77 (0.66, 0.89)
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http://www.ovarianresearch.com/content/5/1/13whether the effect of tubal ligation and hysterectomy on
ovarian cancer risk differs by individual and surgical char-
acteristics as well as considering the potential negative
health effects of these procedures. Additional research also
is needed to further understand the mechanisms behind
these reduced risks.
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